结直肠癌肝转移HAIC：LIOX技术
时间:2022-03-09 23:07来源:www.ynjr.net 作者:杨宁介入医学网
Eackground Liver-directed therapies for metastatic disease may enhance responses to either: - enable curative surgery, - prolong disease-free survival, or - enabling systemic treatment-free periods. Current first line treatment for patient
Eackground
-
Liver-directed therapies for metastatic disease may enhance responses to either:
- enable curative surgery,
- prolong disease-free survival, or
- enabling systemic treatment-free periods.
-
Current first line treatment for patients with inoperable colorectal cancer with liver metastases (CRCLM) is systemic chemotherapy ± a biologic agent.
-
The benefit for patients with RAS mutations has an estimated response rate≤ 50% with standard regimens.
-
Furthermore, patients responding to oxaliplatin often have their treatment course limited due to the dose limiting neuropathy of oxaliplatin.
LIOX is a new locoregional chemotherapy technique designed to:
-
treat CRCLMs with repeated high dose oxaliplatin over a reduced time frame;
-
reduce chemo-induced toxicity/peripheral neuropathy;
-
allow for repeatability;
-
avoid repeated vascular punctures;√
-
An implantable arterial access system with its multicatheter port;
-
The system allows for repeated simultaneous multicatheter access (up to two 8Fr devices or three ZFr devices) without vascular punctures
-
Typical catheters and guidewires needed:
-
5Fr standard angiography caths(90-100cm)
-
0.035 guidewires(exchange length)
-
Multipurpose catheter
-
Exchange length catheters
-
5.5Fr compliant embelectomy catheters
-
micro-occlusion balloon catheters
-
0.014 guidewires
|
------分隔线----------------------------
